Literature DB >> 24767627

A structural model of human ferroportin and of its iron binding site.

Maria C Bonaccorsi di Patti1, Fabio Polticelli, Giovanna Cece, Antimo Cutone, Franco Felici, Tiziana Persichini, Giovanni Musci.   

Abstract

A structural model of human ferroportin has been built using two Escherichia coli proteins belonging to the major facilitator superfamily of transporters. A potential iron binding site was identified in the inward-open conformation of the model, and its relevance was tested through measurement of iron export of HEK293T cells expressing wild-type or mutated ferroportin. Aspartates 39 and 181 were found to be essential for the transport ability of the protein. Noteworthy, the D181V mutation is naturally found in type 4 hemochromatosis with reticuloendothelial system iron retention phenotype. The outward-open conformation of ferroportin was also predicted, and showed that significant conformational changes must occur in the inward- to outward-open transition of ferroportin. In particular, putative iron ligands move several ångströms away from each other, leading to the logical conclusion that the iron binding site is not occupied by the metal in the outward-open conformation of ferroportin.
© 2014 FEBS.

Entities:  

Keywords:  Fpn; hemochromatosis; iron; major facilitator superfamily; molecular modelling

Mesh:

Substances:

Year:  2014        PMID: 24767627     DOI: 10.1111/febs.12825

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  14 in total

1.  Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions.

Authors:  L Tom Vlasveld; Dorine W Swinkels
Journal:  Haematologica       Date:  2018-11       Impact factor: 9.941

2.  Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

Authors:  Sharraya Aschemeyer; Bo Qiao; Deborah Stefanova; Erika V Valore; Albert C Sek; T Alex Ruwe; Kyle R Vieth; Grace Jung; Carla Casu; Stefano Rivella; Mika Jormakka; Bryan Mackenzie; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2017-12-13       Impact factor: 22.113

3.  Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.

Authors:  Vania Manolova; Naja Nyffenegger; Anna Flace; Patrick Altermatt; Ahmet Varol; Cédric Doucerain; Hanna Sundstrom; Franz Dürrenberger
Journal:  J Clin Invest       Date:  2019-12-09       Impact factor: 14.808

4.  Ferroportin 3 is a dual-targeted mitochondrial/chloroplast iron exporter necessary for iron homeostasis in Arabidopsis.

Authors:  Leah J Kim; Kaitlyn M Tsuyuki; Fengling Hu; Emily Y Park; Jingwen Zhang; Jennifer G Iraheta; Ju-Chen Chia; Rong Huang; Avery E Tucker; Madeline Clyne; Claire Castellano; Angie Kim; Daniel D Chung; Christopher T DaVeiga; Elizabeth M Parsons; Olena K Vatamaniuk; Jeeyon Jeong
Journal:  Plant J       Date:  2021-06-21       Impact factor: 7.091

5.  Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin.

Authors:  Reiya Taniguchi; Hideaki E Kato; Josep Font; Chandrika N Deshpande; Miki Wada; Koichi Ito; Ryuichiro Ishitani; Mika Jormakka; Osamu Nureki
Journal:  Nat Commun       Date:  2015-10-13       Impact factor: 14.919

6.  Human macrophage ferroportin biology and the basis for the ferroportin disease.

Authors:  Manuela Sabelli; Giuliana Montosi; Cinzia Garuti; Angela Caleffi; Stefania Oliveto; Stefano Biffo; Antonello Pietrangelo
Journal:  Hepatology       Date:  2017-03-22       Impact factor: 17.425

7.  Insights into the Role of the Discontinuous TM7 Helix of Human Ferroportin through the Prism of the Asp325 Residue.

Authors:  Marlène Le Tertre; Ahmad Elbahnsi; Chandran Ka; Isabelle Callebaut; Gérald Le Gac
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

8.  Epigenetic Regulation of Ferroportin in Primary Cultures of the Rat Blood-Brain Barrier.

Authors:  Steinunn Sara Helgudottir; Lisa J Routhe; Annette Burkhart; Katrine Jønsson; Inge S Pedersen; Jacek Lichota; Torben Moos
Journal:  Mol Neurobiol       Date:  2020-06-15       Impact factor: 5.682

Review 9.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

10.  The SLC40A1 R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanism.

Authors:  Chandran Ka; Julie Guellec; Xavier Pepermans; Caroline Kannengiesser; Cécile Ged; Wim Wuyts; David Cassiman; Victor de Ledinghen; Bruno Varet; Caroline de Kerguenec; Claire Oudin; Isabelle Gourlaouen; Thibaud Lefebvre; Claude Férec; Isabelle Callebaut; Gérald Le Gac
Journal:  Haematologica       Date:  2018-07-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.